. 2025 Feb 5;9:695. Originally published 2024 Nov 27. [Version 2] doi: 10.12688/wellcomeopenres.22498.2

Table 6. First new neurological event over the first 12 months after randomisation.

	First new neurological event		Hazard ratio (95% CI)	p-value	p-value for heterogeneity *
	Dexamethasone	Placebo	Hazard ratio (95% CI)	p-value	p-value for heterogeneity *
All patients of CT or CC genotype	XX/XX	XX/XX	X.XX (X.XX, X.XX)	X.XX
LTA4H genotype - TT - CT - CC	XX/XX XX/XX XX/XX	XX/XX XX/XX	X.XX (X.XX-X.XX) X.XX (X.XX-X.XX)	X.XX X.XX	X.XX
Modified MRC grade - Grade I - Grade II - Grade III	XX/XX XX/XX XX/XX	XX/XX XX/XX XX/XX	X.XX (X.XX-X.XX) X.XX (X.XX-X.XX) X.XX (X.XX-X.XX)	X.XX X.XX X.XX	X.XX
TBM diagnosis - Definite - Probable - Possible	XX/XX XX/XX XX/XX	XX/XX XX/XX XX/XX	X.XX (X.XX-X.XX) X.XX (X.XX-X.XX) X.XX (X.XX-X.XX)	X.XX X.XX X.XX	X.XX

* Heterogeneity was tested with a Cox regression model that included an interaction between treatment effect and subgroup.

CI=confidence interval. LTA4H= leukotriene A4 hydrolase. MRC=Medical Research Council.